Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.49 |
| ▸ | SORD | Q00796 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9557526 | 0.79 | LMNA (0.48) | L3MBTL1LMNASLC6A7SORDKDM4E | |
| SCHEMBL27723124 | 0.79 | SLC6A7 (0.59) | L3MBTL1LMNASLC6A7SORDKDM4E | |
| SCHEMBL6183959 | 0.78 | SORD (0.51) | L3MBTL1LMNASORDKDM4EDRD4 | |
| SCHEMBL18228513 | 0.77 | SORD (0.51) | L3MBTL1LMNASLC6A7SORDKDM4E | |
| SCHEMBL31014265 | 0.77 | SORD (0.51) | L3MBTL1LMNASLC6A7SORDKDM4E | |
| SCHEMBL2320496 | 0.77 | SORD (0.51) | L3MBTL1LMNASLC6A7SORDKDM4E | |
| SCHEMBL3258812 | 0.76 | PLD1 (0.58) | LMNAKDM4EALDH1A1 | |
| SCHEMBL29974045 | 0.76 | PLD1 (0.58) | LMNAKDM4EALDH1A1 | |
| SCHEMBL28690280 | 0.76 | TRIM24 (0.53) | L3MBTL1LMNASLC6A7SORDKDM4E | |
| SCHEMBL2074813 | 0.76 | LMNA (0.54) | L3MBTL1LMNASLC6A7SORDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111491918-B | Aryl and heteroaryl substituted indole compounds | 百时美施贵宝公司 | 2023-10-24 | — | — | CN | claimed |
| CN-111511730-B | Amide substituted indole compounds useful as TLR inhibitors | 百时美施贵宝公司 | 2023-07-25 | — | — | CN | claimed |
| CN-111491918-A | Aryl and heteroaryl substituted indole compounds | 百时美施贵宝公司 | 2020-08-04 | — | — | CN | claimed |
| CN-110337293-A | Therapeutic compound | 新泽西鲁特格斯州立大学 | 2019-10-15 | — | — | CN | claimed |
| CN-101193635-A | Multicyclic compounds and methods of their use | LEXICON GENETICS INC (US) | 2008-06-04 | — | — | CN | claimed |
| CN-111491918-B | Aryl and heteroaryl substituted indole compounds | 百时美施贵宝公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-111511730-B | Amide substituted indole compounds useful as TLR inhibitors | 百时美施贵宝公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-113302183-A | Cyclic ureas | 圣瑞诺有限公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-111511730-A | Amide substituted indole compounds useful as T L R inhibitors | 百时美施贵宝公司 | 2020-08-07 | — | — | CN | disclosed |
| CN-111491918-A | Aryl and heteroaryl substituted indole compounds | 百时美施贵宝公司 | 2020-08-04 | — | — | CN | disclosed |
| CN-110337293-A | Therapeutic compound | 新泽西鲁特格斯州立大学 | 2019-10-15 | — | — | CN | disclosed |
| US-9540392-B2 | Thienopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-10 | — | — | US | disclosed |
| US-9540392-B2 | Thienopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-10 | — | — | US | disclosed |
| EP-2852596-B1 | THIENOPYRIMIDINES | Bayer Pharma AG (DE) | 2016-06-22 | — | — | EP | disclosed |
| US-20150133425-A1 | THIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | US | disclosed |
| US-20150133425-A1 | THIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | US | disclosed |
| CN-104169275-A | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2014-11-26 | — | — | CN | disclosed |
| CN-104159896-A | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2014-11-19 | — | — | CN | disclosed |
| CN-101193635-A | Multicyclic compounds and methods of their use | LEXICON GENETICS INC (US) | 2008-06-04 | — | — | CN | disclosed |
| US-6342503-B1 | ANTIDEPRESSANTS, EATING DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2002-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133425-A1 | THIENOPYRIMIDINES | TYMP, DPYD, TYMS | L3MBTL1 3773/4885LMNA 3790/4885SLC6A7 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.